Canaccord Genuity Group Reaffirms Buy Rating for AngioDynamics (NASDAQ:ANGO)

Posted by Brenda Bartman on Oct 9th, 2026

AngioDynamics (NASDAQ:ANGO – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Canaccord Genuity Group in a report issued on Friday, Benzinga reports. They presently have a $20.00 price target on the medical instruments supplier’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 78.09% from the stock’s current price.

ANGO has been the subject of a number of other reports. Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. HC Wainwright lifted their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

Check Out Our Latest Research Report on AngioDynamics

AngioDynamics Stock Performance

Shares of NASDAQ:ANGO opened at $11.23 on Friday. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29. The firm has a market cap of $472.22 million, a PE ratio of -12.91 and a beta of 0.30. The business has a fifty day moving average of $15.39 and a 200-day moving average of $13.11.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The company had revenue of $80.92 million during the quarter, compared to analyst estimates of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts anticipate that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On AngioDynamics

Several institutional investors have recently modified their holdings of ANGO. Integrated Wealth Concepts LLC bought a new position in shares of AngioDynamics during the 2nd quarter valued at about $38,000. Corient Private Wealth LP bought a new position in shares of AngioDynamics during the 2nd quarter valued at about $134,000. Public Employees Retirement System of Ohio bought a new position in shares of AngioDynamics during the 2nd quarter valued at about $64,000. Bank of America Corp DE bought a new position in shares of AngioDynamics during the 2nd quarter valued at about $4,490,000. Finally, Gallagher Fiduciary Advisors LLC bought a new position in shares of AngioDynamics during the 2nd quarter valued at about $589,000. Institutional investors own 89.43% of the company’s stock.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

Positive Sentiment: AngioDynamics reported fiscal Q1 revenue of $80.9 million, slightly above consensus, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, led by 13.2% growth in Med Tech sales. Auryon sales rose 14.7% and NanoKnife sales climbed 29.0%. AngioDynamics Fiscal Q1 Results
Positive Sentiment: The company reiterated fiscal 2027 revenue guidance of $336 million to $341 million and EPS guidance of $(0.29) to $(0.24), broadly in line with analyst expectations. Canaccord Genuity reaffirmed its Buy rating and maintained a $20 price target, implying substantial potential upside from the referenced $11.23 price. AngioDynamics Outlook
Neutral Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The appointment brings an experienced medical-technology executive to the company, but the leadership change introduces near-term execution uncertainty and contributed to the weak market reaction. CEO Appointment
Negative Sentiment: Despite improved results, AngioDynamics remains unprofitable, with a reported GAAP net loss and negative margins. The company used $15.3 million in operating cash during the quarter and held $34.0 million in cash at quarter-end, heightening concerns about profitability and liquidity. The unchanged guidance also failed to provide a stronger catalyst after the earnings release.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.